What are your top takeaways in Hematologic Malignancies from ASCO 2022?

Each year the American Society of Oncology Annual Meeting offers new or updated information that has the potential to change how we care for our patients. Here I highlight three hematology studies that are highly impactful, and which were rightfully highlighted at ASCO 2022. They serve to reinforce ...

1. The rusfertide presentation by Ron Hoffman was interesting as it’s the first PV drug to essentially eliminate phlebotomy need immediately.

2. The study by Ong looking at the impact of conditioning in transplant outcomes was also very interesting as it challenges the standard of care that fits pat...

1. The LBA4 (DETERMINATION) trial obviously generated a lot of discussion, given no apparent survival benefit and the low use of salvage transplant. There were 3 bispecific presentations, each of which had merits.

2. Abstract 8007 was a further update for teclistamab, which is likely going to be appr...

1. SHINE Study - BR + ibrutinib improves PFS without OS benefit. Lack of OS benefit is not necessarily surprising given salvage regimens. Of concern would be the non-disease-related deaths in the experimental arm and the lack of benefit in high risk patient populations. Not currently practice-changi...